Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBH589 plus trastuzumab in HER2-positive metastatic breast cancer after progression on trastuzumab
2007-002449-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat and trastuzumab in breast cancer (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicity during dose escalation, Maximum tolerated dose and 1 more. Started Oct 2007; status: completed.
02
Drugs
panobinostattrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-002449-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002449-19.